Rotigotine helps restless legs syndrome in a 6-month controlled study in the US

A total of 505 participants showed significant improvements in restless legs syndrome symptoms with 2 to 3 mg/24 hr rotigotine compared to placebo.

• The IRLS sum score decreased significantly from baseline to the end of the 6-month period for participants receiving rotigotine.
• Rotigotine at doses of 2 mg/24 hr and 3 mg/24 hr was superior to placebo, with adjusted treatment differences of -4.5 and -5.2, respectively.
• Clinical global impressions also improved significantly, with adjusted differences of -0.65 for 2 mg/24 hr and -0.9 for 3 mg/24 hr compared to placebo.
• Mild to moderate skin reactions occurred in 27% of rotigotine subjects, while known side effects included nausea (18.1%) and headache (11.6%).
• Efficacy of rotigotine was maintained throughout the entire 6-month double-blind trial.

Simplified